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Abstract 
Objectives: 
The aims of this study are to evaluate whether serum pancreatic enzyme levels could be used to 
aid screening for chronic pancreatitis (CP). 
Methods: 
170 healthy volunteers were screened and prospectively enrolled in the control group. 150 
patients who were diagnosed with calcific CP were enrolled in the patient group by retrospective 
review. Serum amylase and lipase levels were compared between the two groups. 
Results: 
The mean values ± S.D. of the control group were compared with those of the patient group for 
serum amylase level (48.1 ± 13.2 U/L vs. 34.8 ± 17.2 U/L, p<0.001), and serum lipase level (26.4 
± 11.3 U/L vs. 16.3 ± 11.2 U/L, p<0.001). On the receiver operation characteristic curve analysis 
for amylase level, area under the curve was 0.740 (95% confidence interval), and sensitivity and 
specificity were 38.7% and 94.1%, respectively, with a cut-off value of 27.5 U/L. On the receiver 
operation characteristic curve analysis for lipase level, area under the curve was 0.748 (95% 
confidence interval), and sensitivity and specificity were 33.3% and 95.9%, respectively, with a cut-
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off value of 10.5 U/L. 
Conclusions:  
Our results suggest that low serum pancreatic enzyme levels can be used to aid in detection of CP.  
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Introduction 
Chronic pancreatitis (CP) is defined as progressive inflammatory destruction of pancreatic 
secretary parenchyma with replacement by fibrous tissue, resulting generally in irreversible 
dysfunction of both endocrine and exocrine pancreatic function (1-2). CP is usually diagnosed 
based on clinical-historical information, results of imaging findings, pancreatic functional tests and 
chronically or intermittently elevated pancreatic serum enzymes (3, 4). Serum amylase and lipase 
are obtained in nearly all suspected CP patients. When low serum values are obtained, does the 
clinician use this information to aid in CP diagnosis or is the value ignored (or perhaps considered 
laboratory error)? 
The lipase expression can be detected to varying extent in the lingual salivary glands, gastric 
fundus, duodenum, liver, and the adipose tissue. But the main organ of lipase secretion is the 
pancreas. Total pancreatectomy patients commonly have low serum lipase levels (5, 6). In CP, 
damage may affect pancreatic enzyme synthesis and entry into and clearance from the circulation. 
This may result in low serum enzyme levels. In the pathologic tissue analysis, pancreatic tissue in 
CP demonstrates decrease of both amylase and lipase activity. Notably, amylase activity is more 
decreased than lipase activity (7).  
The correlation between severe exocrine insufficiency and low pancreatic juice enzyme levels is 
well known. Older reports note low serum pancreatic enzymes, especially lipase, in up to 50% of 
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patients with CP (8-11). Although the role of elevated serum lipase levels as a valid tool for 
diagnosing acute pancreatitis and acute episodes of CP has been well established, the low serum 
lipase levels in CP have not yet attracted much recent attention. Low serum amylase and lipase 
levels in CP are not discussed in several recent publications (3, 12-19). Serum amylase and lipase 
remain as readily available and inexpensive tests. Methodologies for pancreatic enzymes 
measurement reports from older literature earlier than the year 2000 are different from that used 
in many modern laboratories.  
The aims of this study are 1. To determine if amylase and lipase levels as assessed by modern day 
methods are low in a portion of CP patients, 2. To compare serum pancreatic enzyme levels 
between CP patients and healthy controls, and 3. To evaluate whether serum pancreatic enzyme 
levels could be used to aid screening for CP. 
 
Methods 
Healthy volunteers were screened and prospectively enrolled in the control group. Patients who 
were diagnosed with calcific CP and underwent ERCP were enrolled in the patient group. Serum 
amylase and lipase levels were compared between the two groups. This study was approved by 
Indiana University Institutional Review Board prior to the commencement of the study. 
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1) Control group
Healthy paid volunteers were screened and prospectively enrolled in the control group from April 
1, 2014 to March 15, 2015. Informed consent was obtained from all such volunteers before 
enrollment. Inclusion criteria and exclusion criteria were represented in the Table 1. Aliquots blood 
samples from a single draw were analyzed for serum pancreatic enzyme levels. 
2) Patient group
Patients who were diagnosed with calcific CP and underwent ERCP in Indiana University Health 
between January 1, 2012 and May 31, 2014 were enrolled in the patient group. All information 
was obtained by retrospective medical record review from patients identified through the IU ERCP 
procedure database. Calcific CP was diagnosed based on clinical symptoms and pancreatic 
calcifications detected by imaging studies (CT, MRI, or ERCP). Serum amylase and lipase were 
obtained and analyzed a few hours before the ERCP by the routine clinical laboratory of the 
Indiana University Health. Patients were excluded from the study if they were younger than 18 
years or older than 79 years or pregnant or had a condition, such as chronic kidney disease, 
previous gastrointestinal or pancreatic surgery that may affect serum amylase and lipase levels. 
3) Analysis of serum pancreatic enzymes
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All serum amylase level and lipase level in the both groups were measured using same automated 
chemistry analyzer (AU 5822 analyzer; Beckman Coulter, Inc., Brea, CA). Our validated reference 
range for amylase and lipase are between 19 U/L and 86 U/L, and between 7 U/L and 59 U/L, 
respectively.  
Serum amylase and lipase levels were compared between the two groups. If a patient had blood 
drawn several times during enrollment period, the lowest level among the results was used for 
analysis. Patients with an abnormal high serum pancreatic enzyme level before ERCP were enrolled 
in the study only when their levels returned to below the upper limit of normal and pain was 
resolved or improved after ERCP.  
 
4) Statistical analysis 
Pearson’s chi square test and student t-test were used to analyze the differences between two 
groups. Student t-test was used to analyze the variables among the subgroups in control group. 
Receiver operating characteristics (ROC) curve analysis was constructed and the area under the 
curve (AUC) was calculated to determine the diagnostic performance of serum pancreatic enzymes. 
The level of variables were described as mean ± standard deviation (S.D.). P<0.05 was considered 
significant. Statistical analysis was performed with IBM® SPSS® Statistics (Version 22.0.0; SPSS Inc., 
Chicago, IL, USA). 
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Results 
 
A total of 180 healthy volunteers were screened and enrolled in the control group. Ten healthy 
volunteers were excluded due to abnormal high levels of pancreatic enzymes (5.6%), resulting in a 
total of 170 healthy volunteers finally enrolled in the control group (44 men, 126 women with a 
mean age of 48.1 years; range, 20-78 years). A total of 220 patients were identified with calcific CP 
and underwent 370 ERCP procedures, of which 70 patients were excluded: 33 patients with 
persistent elevations of pancreatic serum enzyme levels; 11 patients with history of other 
gastrointestinal disease or previous gastrointestinal operation; 9 patients with age <18 or >79; 9 
patients with inadequate information; 5 patients with chronic kidney disease; 3 patients with 
neoplastic disease. A total of 150 patients (76 men, 74 women with a mean age of 54.0 years; 
range, 23-78 years) were enrolled in the patient group (Fig. 1). 
The characteristics of the study participants are presented in Table 2. There were significant 
differences in mean age (mean values ± S.D.; 48.1 ± 15.9 vs. 54.0 ± 12.2, respectively, p<0.001) 
and sex ratio (male : female; 44 : 126 vs. 76 : 74, respectively, p<0.001) between control group 
and patient group due to differences of frequency of volunteer subgroups. The mean serum 
amylase level was significantly higher in the control group compared with that of the patient 
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group (normal range, 19-86 U/L: 48.1 ± 13.2 U/L vs. 34.8 ± 17.2 U/L, respectively, p<0.001). The 
mean lipase level was also significantly higher in the control group compared with that of the 
patient group (normal range, 7–59 U/L: 26.4 ± 11.3 U/L vs. 16.3 ± 11.2 U/L, respectively, p<0.001) 
(Fig. 2). 
Because of non-equal distribution of sex and age in the volunteer group, subgroup analyses were 
done in the control for the evaluation of age-related and sex-related differences. Between 
younger-age (age 18-49) and older-age (age 50-79) subgroups, there was no significant difference 
of serum amylase and lipase levels (amylase: 46.9 ± 11.6 U/L vs. 45.0 ± 11.4 U/L, respectively, 
p=0.326; lipase: 24.1 ± 10.1 U/L vs. 25.9 ± 10.7, respectively, p=0.303). Between male and female 
subgroups, there was no significant difference of serum amylase and lipase levels (amylase: 46.5 ± 
14.2 U/L vs. 48.7 ± 12.8 U/L, respectively, p=0.362; lipase: 29.6 ± 13.5 U/L vs. 25.3 ± 10.2 U/L, 
respectively, p=0.058) (Table 3). 
Interestingly, no one in the healthy volunteer group had values of serum amylase and lipase levels 
below the reference range (normal range). Using mean value minus 2 S.D. of control group, 45 
patients (30%) had low amylase level (mean level, 16.5 ± 4.7 U/L), 28 patients (18.7%) had low 
lipase level (mean level, 3.1 ± 0.4 U/L), 16 patients (10.7%) had both levels low and 57 patients 
(38.0%) had either of both levels low. 
We next generated the receiver operation characteristic (ROC) curves to assess the potential 
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usefulness of low serum pancreatic enzyme levels as diagnostic modalities for CP (Fig. 3 and Table 
4). On the ROC curve analysis for amylase level, AUC was 0.740 (95% confidence interval), and 
sensitivity and specificity were 70.0% and 70.6%, respectively, with an optimum diagnostic cut-off 
value of 41.5 U/L. Specificity of serum amylase level for diagnosis of CP was 94.1% with a cut-off 
value of 27.5 U/L. On the ROC curve analysis for lipase level, AUC was 0.748 (95% confidence 
interval), and sensitivity and specificity were 69.3% and 68.8%, respectively, with an optimum 
diagnostic cut-off value of 19.5 U/L (Fig. 3 and Table 3). Specificity of serum lipase level for 
diagnosis of CP was 95.9% with a cut-off value of 10.5 U/L. If both serum amylase and lipase 
levels are lower than normal range, sensitivity and specificity are 10.7% (16/150) and 100% 
(170/170), respectively. If either serum amylase or lipase level is lower than normal range, 
sensitivity and specificity are 30.0% (45/150) and 100% (170/170), respectively. 
 
Discussion 
 
Nearly every patient with clinically suspected CP has a serum amylase and lipase drawn. If values 
are elevated, suspicions for pancreatic diseases are increased and further studies are often done. If 
values are normal, no specific next step is suggested. If values are low, many clinicians (personal 
observation) have no increased suspicion of CP. Our study was done to re-evaluate the utility of 
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low serum pancreatic enzyme levels for diagnosing chronic pancreatitis. 
Our results show that patients with established calcific CP (with obviously advanced disease) had 
significantly lower levels of serum pancreatic enzymes than healthy control group. Furthermore, 
when compared to healthy control group, 57 patients (38%) out of 150 patients had at least 1 
enzyme level more than 2 S.D. below the levels of control group. These results suggest that low 
levels in routine pancreatic serum enzyme tests should not be deemed “normal” nor dismissed 
clinically unimportant. 
Low serum lipase and amylase levels in CP were observed long ago (8-11). Could this observation 
apply to currently used laboratory methodology? This study confirms prior studies and 
emphasizes the diagnostic values of low serum pancreatic enzymes. We conducted an ROC curve 
analysis to determine the diagnostic possibility of detecting patients with a CP. As can be seen in 
Fig. 3 and Table 4, the AUC for serum amylase level and serum lipase level were both greater than 
0.7, with sensitivity and specificity ranging between 65% and 70% depending on the optimal cut-
off value. These values were somewhat different from the values presented by the diagnostic 
modalities of CP, but the specificity increased rapidly to beyond 90% with lower cut-off values. 
Specificity of serum amylase was 94.1% with cut-off level of 27.5 U/L and 100% when the level 
was lower than 18.5 U/L. Specificity of serum lipase was 95.9% when the cut-off level was 10.5 U/L 
and 100% when the cut-off level was lower than 7.5 U/L. These results suggest that normal 
14 
subjects do not show values below a certain level and that this cut-off may be useful for the 
diagnosis of CP. The clinician should not ignore low serum amylase and lipase levels as they 
suggest chronic pancreatitis in absence of pancreas resection surgery.   
Previously reported noninvasive or indirect laboratory tests have highly variable accuracy in 
suggesting a diagnosis of CP depending on the severity of the disease (18, 19). Serum trypsin 
level has similarily been found to be low in up to 50% of calcific CP patients and moderate 
sensitivity in late disease state with steatorrhea. Some reports mentioned this in discussion of 
chronic pancreatitis, while the sensitivity is at least intermediate, the specificity is near 100% (10, 
18, 19). This would appear to have equal diagnostic values for amylase and lipase low values. The 
serum trypsin assay has not replaced amylase and lipase in clinical practice due to requiring 
several days to obtain a result, and two-fourfold more expensive than serum amylase and lipase 
levels in our hospital. 
Our contention is clinically to take further advantage of serum amylase and lipase values which 
are already drawn on virtually all suspected pancreatic disease patients. Low analysis cost of 
serum amylase and lipase levels are especially valuable in 3rd world countries. Clinicians should 
not overlook low pancreatic enzyme values but should suspect chronic pancreatitis and 
recommend further detailed examinations. 
A large-scale, prospective, follow-up study based on our results would be able to establish critical 
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diagnostic basis, such as using serum pancreatic enzyme level as an economic, long-term follow-
up in patients with symptoms of CP but unremarkable findings from routine tests. If a patient’s 
levels are below certain levels or continuously decreasing, more accurate diagnostic tests can be 
recommended more confidently for confirmation of CP. Our study was not designed to detect the 
difference in pancreatic enzyme levels depending on the severity of CP or in the course of disease 
progression from recurrent pancreatitis to chronic calcific pancreatitis in a long-term follow-up. 
These could be addressed in future studies. 
Limitations of our study are as follows. Healthy volunteers were enrolled prospectively but the 
subjects in the patient group were enrolled retrospectively. Although there is no statistical 
difference of serum amylase and lipase level between male and female subgroup, men and 
women were not evenly distributed across the healthy group due to low rate of volunteering in 
males, especially younger males. Patients with early-stage CP were not involved in this 
comparative study, and those differences in terms of the severity or cause of CP could not be 
investigated. We are not aware of other clinical conditions with low serum amylase and lipase 
level (except for resection surgery of pancreas or salivary glands, chronic salivary gland disease, or 
pancreatitis with extensive necrosis, etc.). 
In conclusion, our results suggest that low serum amylase and lipase levels should not be 
discarded for patients, and that further testing may be warranted if there is the possibility of 
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underlying pancreatic disease. Also, low serum amylase and lipase levels as detected by modern 
methodology laboratory can be used to aid in the screening of CP. These results confirm previous 
studies stating up to 50% sensitivity for CP diagnosis. Further studies in non-calcific chronic 
pancreatitis are needed to clarify the pancreatic enzyme levels in regards to the demographic 
factors and severity status of chronic pancreatitis.  
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Table 1. Inclusion and exclusion criteria for control group 
Inclusion 
criteria 
 Age 18 - 79. 
 General good health. 
 Body weight 110 pounds (50 kg) or greater. 
 Agrees to participate and signs consent form. 
 Be able to complete General Health/Gastrointestinal Health History Survey. 
 Be willing to have bloodwork drawn. 
Exclusion 
criteria 
 History of gastrointestinal disorders: any pancreatic disorder, bowel 
obstruction or inflammatory bowel disease (Crohn’s disease or ulcerative 
colitis), peptic ulcer disease, gallstones or gastrointestinal tumors (any type). 
 History of ovarian tumors (any type).  
 History of lung tumors (any type).  
 Major health disorders: diabetes, liver disorders, arthritis (osteoarthritis 
acceptable), myocardial infarction, or chronic obstructive pulmonary disease 
(chronic bronchitis or emphysema). 
 Family history of chronic pancreatitis or cystic fibrosis.  
 Pain in the upper abdomen greater than 5 days per year. 
 Alcohol intake greater than 2 drinks per day. 
 History of alcohol use of 10 drinks per day for greater than 2 years. 
 Does not wish to participate or to consent to have their laboratory results 
utilized in future studies. 
 Pregnant. 
 Cigarette smoking history of more than 1 pack per day for 5 years or more. 
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Table 2. Baseline characteristics of control group and patient group 
 
 Control Group 
(n=170) 
Patient Group 
(n=150) 
P value 
Age (years) 48.1 ± 15.9  54.0 ± 12.2 <0.001 
Sex (male) 44 (25.9) 76 (50.7) <0.001 
Serum amylase (U/L)* 48.1 ± 13.2 34.8 ± 17.2 <0.001 
Serum lipase (U/L)** 26.4 ± 11.3 16.3 ± 11.2 <0.001 
Values are presented as mean values ± S.D. or n (%). 
* Normal value: 19-86 U/L. 
** Normal value: 7-59 U/L 
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Table 3. Age related and sex related subgroup analysis in control group 
Age related subgroup P value 
Age 18-49
(n=78) 
Age 50-79 
(n=73) 
Serum amylase (U/L)* 46.9 ± 11.6 45.0 ± 11.4 0.326 
Serum lipase (U/L)** 24.1 ± 10.1 25.9 ± 10.7 0.303 
Sex related subgroup 
Male (n=44) Female (n=126) 
Serum amylase (U/L)* 46.5 ± 14.2 48.7 ± 12.8 0.362 
Serum lipase (U/L)** 29.6 ± 13.5 25.3 ± 10.2 0.058 
Values are presented as mean values ± S.D. 
* Normal value: 19-86 U/L.
** Normal value: 7-59 U/L 
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Table 4. Sensitivity and specificity of serum pancreatic enzyme levels for chronic pancreatitis using 
variable cut-off values 
 Level (U/L) Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
Predictive 
Value (%) 
Serum amylase 
(Normal: 19-86 U/L) 
18.5 
27.5 
32.5 
38.5 
41.5 
16.0 
38.7 
49.3 
64.0 
70.0 
100 
94.1 
90.6 
80.0 
70.6 
100 
85.3 
82.2 
73.8 
67.8 
57.4 
63.5 
67.0 
71.6 
72.7 
Serum lipase 
(Normal: 7-59 U/L) 
7.5 
10.5 
13.5 
15.5 
19.5 
27.3 
33.3 
45.3 
52.7 
69.3 
100 
95.9 
89.4 
82.9 
68.8 
100 
87.7 
79.1 
73.1 
66.2 
60.9 
62.0 
65.0 
66.5 
71.8 
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Figure legends 
Figure 1. Study enrollment flowchart. A total of 180 healthy volunteers were screened and 170 volunteers 
were enrolled in the control group. A total of 220 patients were diagnosed with chronic calcific pancreatitis 
and 150 patients were enrolled in the patient group. 
24 
Figure 2. Results of serum pancreatic enzyme level analysis between control group and patient group. Scatter 
dot graphs show significantly higher levels of serum pancreatic enzymes in the control group compared with 
those of the patient group (Student t-test). 
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Figure 3. Receiver operation characteristic (ROC) curve analysis for the diagnostic performance of serum 
amylase and lipase level for detection of chronic calcific pancreatitis. Area under the curves (AUCs) are 0.740 
(95% confidence interval) for serum amylase level, and 0.748 (95% confidence interval) for serum lipase level. 
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